Search
The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule.
Christopher Asha André Dr Anita Blyth Bowen Schultz Campbell MBBS (Hons) DCH FRACP FRCPA PhD BA MBBS DCH FRACP PhD GAICD FAHMS OAM MBChB, PhD, FRACP
18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine will have higher antibody levels
To determine the contribution of RSV to the subsequent development of severe asthma in different subgroups of children at risk of severe RSV disease.
Dosing errors are the most commonly reported medication error in children. Dosing is often prescribed per weight or based on body area.
The PCV7 was introduced to prevent IPD in WA Aboriginal people in 2001 to a lesser extent in older people.
Confirm the generalised IgE-trophic activity of the DTaP vaccine in pre-schoolers and demonstrate similar (albeit transient) effects in infants
The results suggest that though the risk for RSV in the NICU remains low, personnel clothing are contaminated with RSV-RNA and may have a role in transmission
This article discusses the rising prevalence of pertussis disease in countries which have switched to acellular vaccines.
This paper reports the results from the safety surveillance of influenza vaccines in children in Australia, in 2015.